ALLR (Allarity Therapeutics) Accounts Payable: $4.24 Mil (As of Mar. 2026)

What is Allarity Therapeutics Accounts Payable?

Allarity Therapeutics ALLR -0.76% 26 Accounts Payable is $4.24 Mil as of Mar. 2026. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Allarity Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $4.24 Mil.

Allarity Therapeutics's quarterly Accounts Payable declined from Sep. 2025 ($4.60 Mil) to Dec. 2025 ($4.28 Mil) and declined from Dec. 2025 ($4.28 Mil) to Mar. 2026 ($4.24 Mil).

Allarity Therapeutics's annual Accounts Payable declined from Dec. 2023 ($8.42 Mil) to Dec. 2024 ($4.18 Mil) but then increased from Dec. 2024 ($4.18 Mil) to Dec. 2025 ($4.28 Mil).

Allarity Therapeutics Accounts Payable Related Terms

Allarity Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics Accounts Payable Chart

Allarity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Accounts Payable

Get a 7-Day Free Trial

0.70

6.25

8.42

4.18

4.28

Allarity Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Accounts Payable	Get a 7-Day Free Trial															4.35	4.61	4.60	4.28	4.24

26GF Score

Allarity Therapeutics Inc ALLR

Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Allarity Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →

What does a Accounts Payable of $4.24 Mil mean?

Allarity Therapeutics (ALLR) has a Accounts Payable of $4.24 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Allarity Therapeutics and its competitors.

Is Allarity Therapeutics' Accounts Payable too high?

Allarity Therapeutics' current Accounts Payable is $4.24 Mil. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.

How does Allarity Therapeutics' Accounts Payable compare to NCEL and LPCN?

Allarity Therapeutics' Accounts Payable of $4.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Accounts Payable for a Biotechnology company?

A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Accounts Payable mean?

A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current Accounts Payable is $4.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Allarity Therapeutics stock overvalued right now?

Allarity Therapeutics (ALLR) has a current Accounts Payable of $4.24 Mil. The current Accounts Payable is $4.24 Mil. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Accounts Payable calculated?

Accounts Payable is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current Accounts Payable is $4.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies NCEL LPCN PTN CLRB OTLC VYNE PLUR MRKR CVM AEON VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689

Website https://www.allarity.com

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

26GF Score

Get the complete analysis for ALLR

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.29

Price

View ALLR Analysis

See Accounts Payable data for all stocks →